Adastra Labs is retracting comments made in a February news release implying they had recieved approval to distribute cocaine.
Last month, Health Canada approved an amendment to the Langley-based cannabis company’s Controlled Drug and Substances Dealer’s License.
In the original release, Adastra implied that the amendment allowed them to possess, produce, and sell up to 250 grams of cocaine.
But, both the company and Health Canada have now issued statements to correct any misconceptions from the original statement.
They say that the amendment only allows them to sell cocaine to other licensed dealers and health care providers, and not to the general public.
It also only allows them to manufacture or synthesize the drug for medical or research purposes.
Comments